1)Matas AJ, Smith JM, Skeans MA, et al:OPTN/SRTP 2012 annual data report:kidney. Am J Transplant 14(suppl 1):11-44, 2014
2)日本移植学会・日本臨床腎移植学会:腎移植臨床登録集計報告(2014)2013年実施症例の集計報告と追跡調査結果.移植49:240-260,2014
3)Collins AJ, Foley RN, Gilbertson DT, et al:United states renal data system public health surveyllance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl 5:2-7, 2015
4)政金生人,中井 滋,尾形 聡,他:わが国の慢性透析療法の現況.透析会誌48:1-32,2015
5)Mendelssohn DC, Mujais SK, Soroka SD, et al:A prospective evaluateon of renal replacement therapy modality eligibility. Nephrol Dial Transplant 24:555-561, 2009
6)Cosio FG, Alamir A, Yim S, et al:Patient survival after renal transplantation:I. The impact of dialysis pre-transplant. Kidney Int 53:767-772, 1998
7)Meier-Kriesche HU, Port FK, Ojo AO, et al:Effect of waiting time on renal transplant outcome. Kidney Int 58:1311-1317, 2000
8)Foley RN, Parfrey PS, Hamett JD, et al:Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379-1385, 1996
9)Longeneker JC, Coresh J, Powe NR, et al:Traditional cardiovascular disease risk factors in dialysis patients compared with the general population:The CHOICE study. J Am Soc Nephrol 13:1918-1927, 2002
10)Moe SM:Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36(suppl 2):51-62, 2006
11)Fellström BC, Jardine AG, Schmieder RE, et al:Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360:1395-1407, 2009
12)Wanner C, Krane V, März W, et al:Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005
13)Helantera I, Salmela K, Kyllonen L, et al:Pretransplant dialysis duration and risk of death after kidney transplantation in the current era. Transplantation 98:458-464, 2014
14)Sarnak MJ, Levey AS, Schoolwerth AC, et al:Kidney disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42:1050-1065, 2003
15)Meier-Kriesche HU, Port FK, Ojo AO, et al:Effect of waiting time on renal transplant outcome. Kidney Int 58:1311-1317, 2000
16)Kasiske BL, Snyder JJ, Matas AJ, et al:Preemptive kidney transplantation:the advantage and the advantaged. J Am Soc Nephrol 13:1358-1364, 2002
17)Ylian SL and Weimar W:Early living donor kidney transplantation:A review of the associated survival benefit. Transplantation 87:317-318, 2009
18)Grams ME, Massie AB, Coresh J, et al:Trends in the timing of pre-dmptive kidney transplantation 22:1615-1620, 2011
19)Friedewald JJ and Reese PP:The kidney-first initiative:What is the current status of preemptive transplantation? Adv Chronic Kidney Dis 19:252-256, 2012
20)Riffaut N, Lobbedez T, HaZZAN M, et al:Access to preemptive registration on the waiting list for renal transplantation:a hierarchical modeling approach. Trnaspl Int 28:1066-1073, 2015
21)Courtney AE and Maxwell AP:The challenge of doing what is right in renal transplantation:Balancing equity and utility. Nephron Clin Pract 111:c62-c68, 2009
22)Petrini C:Preemptive kidney transplantation:Ethical issues. Ann Ist Super Sanita 45:173-177, 2009
23)Coorey GM, Paykin C, Singleton-Driscoll LC, et al:Barriers to preemptive kidney transplantation:a single center questionnaire study. Am J Nurs 109:28-37, 2009
24)Knight RJ, Teeter LD, Grafiss EA, et al:Barriers to preemptive renal transplantation. Transplantation 99:576-579, 2015
25)Haller M, Gutjahr G, Kramar R, et al:Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 26:2988-2995, 2011
)conference. Clin J Am Soc Nephrol 3:471-480, 2008
27)Inoue T, Satoh S, Numakura K, et al:Correlations between pretransplant dialysis duration, bladder capacity, and prevalence of vesicoureteral reflux to the graft. Transplantation 92:311-315, 2011